secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001193125-24-248694
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint closes upsized $161M public offering; net proceeds ~$151.1M for DURAVYU development
--------------------------------------------------------------------------------

- Closed offering of 14,636,363 shares at $11.00/share, including full underwriter option exercise for 1,909,090 additional shares.
- Net proceeds of ~$151.1M after underwriting discounts and expenses; original offering was upsized from $125M to $161M gross.
- Proceeds to fund DURAVYU clinical development for wet AMD & DME, early-stage pipeline, and general corporate purposes.
- Joint book-runners: J.P. Morgan, Citigroup, Guggenheim Securities; co-managers: Baird, Mizuho, Jones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000119312524248694/0001193125-24-248694-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000119312524248694/d904414d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-248694

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer